Syneos Health (NASDAQ:SYNH) had its target price lifted by equities research analysts at SunTrust Banks to $55.00 in a research note issued on Thursday, The Fly reports. The firm currently has a “buy” rating on the stock. SunTrust Banks’ price objective would indicate a potential upside of 31.26% from the company’s current price.
A number of other research firms have also issued reports on SYNH. TheStreet raised Syneos Health from a “c” rating to a “b-” rating in a report on Monday, November 6th. BidaskClub raised Syneos Health from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. KeyCorp reissued a “buy” rating and issued a $50.00 target price on shares of Syneos Health in a report on Thursday, January 4th. Credit Suisse Group reissued a “buy” rating and issued a $52.00 target price on shares of Syneos Health in a report on Thursday, January 4th. Finally, Robert W. Baird lowered Syneos Health to an “outperform” rating and dropped their target price for the company from $67.00 to $46.00 in a report on Friday, November 10th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $49.44.
Syneos Health (SYNH) opened at $41.90 on Thursday. The stock has a market capitalization of $3,735.55, a P/E ratio of -72.24, a PEG ratio of 1.05 and a beta of 0.80. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.99. Syneos Health has a twelve month low of $31.10 and a twelve month high of $61.10.
A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new position in Syneos Health during the fourth quarter worth $23,570,000. Municipal Employees Retirement System of Michigan acquired a new position in Syneos Health during the fourth quarter worth $741,000. Finally, Globeflex Capital L P acquired a new position in Syneos Health during the fourth quarter worth $210,000. 96.41% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “SunTrust Banks Increases Syneos Health (SYNH) Price Target to $55.00” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3230132/suntrust-banks-increases-syneos-health-synh-price-target-to-55-00.html.
Syneos Health Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.